Can you buy lagging pharma stocks
Are you also looking for information on can you buy lagging pharma stocks, that's right, I have carefully organized this article on can you buy lagging pharma stocks, it should be able to answer your questions, and more information related to can you buy lagging pharma stocks, you can search in the upper right corner.
Can you buy lagging pharmaceutical stocks
Different people have different views on whether lagging pharmaceutical stocks are worth investing in.
Some people believe that the pharmaceutical industry has the advantage of being rarely affected by the macro-economy and resistant to economic cycles, while favorable policies can promote the profitability of pharmaceutical companies in the long term, so they think it is worth investing in. In addition, stagnant stocks, that is, stock prices are at a high level, stagnant or declining performance, while the price-earnings ratio is at a high valuation, which means that there is some risk.
But there is also the view that the lagging stocks in the pharmaceutical industry should maintain a cautious attitude, because once there is negative news, may cause a relatively large impact on such stocks, and investment in lagging stocks, you must have to such stocks are very good in the report before you dare to intervene, so that the risk is relatively large.
In short, you need to decide whether to buy lagging pharmaceutical stocks based on your own risk tolerance, investment objectives and understanding of the industry. At the same time, it is important to note that any investment involves risk and needs to be treated with caution.
Stocks with Lagging Pharmaceutical Communications
The following are some stocks with lagging pharmaceutical communications:
__ Pientzehuang, or Pientzehuang Pharmaceutical Co, Ltd, the company's net profit in the first quarter of 2021 was NT$2.778 billion, a year-on-year increase of 14.96%.
__ Yunnan Baiyao, or Yunnan Baiyao Group Co, Ltd, the company reported net profit of 2.334 billion yuan for the first quarter of 2021, up 19.87 percent year-over-year.
__ Hengrui Medicine, or Jiangsu Hengrui Medicine Co, Ltd, the company reported net profit of 1.237 billion yuan for the first quarter of 2021, up 12.99 percent year-over-year.
__ Fosun Pharma, or Shanghai Fosun Pharmaceutical Co, Ltd, reported net profit of 1.053 billion yuan for the first quarter of 2021, up 17.57 percent year-over-year.
__Lizhu Group, or Lizhu Pharmaceutical Group Co, Ltd, the company reported net profit of 1.008 billion yuan for the first quarter of 2021, up 15.46% year-over-year.
__ Zhejiang Medicine, or Zhejiang Xinchang Pharmaceutical and Chemical Co, Ltd, the company reported net profit of 568 million yuan for the first quarter of 2021, up 14.68 percent year-on-year.
__ Healthyuan, or Guangdong Healthyuan Pharmaceutical Group Co, Ltd, reported net profit of 458 million yuan for the first quarter of 2021, up 14.13 percent year-over-year.
The above are some of the stocks that are lagging in pharma communication, but it does not mean that these stocks will definitely rise or fall in the future. Investors should make decisions based on their own risk tolerance and investment objectives. At the same time, the trend of the pharmaceutical industry and the policy environment will also have an impact on the share price of the relevant listed companies.
Stagnant and Low Valuation Pharmaceutical Stocks
Stagnant and Low Valuation Pharmaceutical Stocks are:
1. Pientzehuang: The company owns a rich product line, a strong brand and channel advantages, and it is the most important Chinese medicine product research and development and production enterprise in China, which integrates pharmaceutical research and development, pharmaceutical manufacturing and pharmaceutical circulation.
2. Jianmin Group: it is a modernized manufacturing enterprise of traditional Chinese medicine, mainly engaged in the research and development, manufacturing and sales of medicines.
3. Baiyunshan: the company is one of the largest pharmaceutical companies in China, with products covering a wide range of fields, including antibiotics, central nervous system drugs, cardiovascular system drugs, antitumor drugs, digestive system drugs and so on.
4. Kang Enbei: It is a group integrating pharmaceutical research and development, pharmaceutical industry, and commercial distribution, with five industrial companies and two directly-affiliated pharmaceutical operating companies, and nearly 200 product specifications.
5. Shouxiangu: It is a modern high-tech enterprise integrating R&D, production and sales of Ganoderma lucidum-based health care products and health care instruments.
6. Dong'a Colla Corii Asini: It is a professional manufacturer and supplier of Colla Corii Asini series products, with production lines ranging from raw donkey skin to Colla Corii Asini tablets, Colla Corii Asini powder, Colla Corii Asini syrup, Liquid Colla Corii Asini, Colla Corii Asini granules and other series products.
It should be noted that the above stock recommendation is only for your investment to provide reference, stock investment is very risky, investment should be cautious.
Lagging Pharmaceutical Stocks Analysis
On lagging pharmaceutical stocks, different people have different views. Some people think that the valuation premium of pharmaceutical stocks in the gradual repair, pharmaceutical stocks, "gold partner" event catalyst will continue to interpretation, in favor of the relevant lagging pharmaceutical standard valuation repair. Some people believe that the fundamentals of the pharmaceutical and biological plate is still sound, part of the sub-industry is still expected to maintain a high boom, continue to recommend the core track, innovative pharmaceuticals, traditional Chinese medicine, post-epidemic recovery, pharmaceutical services and pharmacies and other five major lines. It is also believed that the pharmaceutical industry has both growth and consumption attributes, the industry's overall beta performance is expected to usher in an upward cycle.
However, there are also views that are pessimistic about the prospects for lagging pharmaceutical stocks. If you stand at this point in time and still hold strong beliefs about lagging pharmaceuticals, you need to have a very deep understanding and knowledge of the industry, as well as sufficient risk tolerance.
In short, for lagging pharmaceutical stocks, investors should decide whether to invest based on their own investment objectives and risk tolerance. At the same time, it should be noted that investment is risky, investors should be careful decision-making.
Lagging Pharmaceutical Stocks Leaders
By the epidemic and drug policy, the pharmaceutical sector underperformed, and some pharmaceutical stocks showed signs of lagging. Here are the leading stocks in the pharmaceutical sector in 2023:
__ WuXi AppTec, the company is a leading global biopharmaceutical service provider, providing new drug development and manufacturing services to global biopharmaceutical companies.
__Myriad Medical, the company's product line covers medical imaging, in vitro diagnostics, high-end medical equipment and so on.
__Tiger Pharmaceuticals, the company is a leading domestic company specializing in clinical research services and clinical pharmacology services.
__Contact Bio, the company is one of the key players in the domestic vaccine industry, with products covering inactivated vaccines, genetically engineered protein vaccines, viral vector vaccines, and CAR-T cell therapeutic products based on gene editing technology.
__ Zhifei Bio, the company's core products are novel coronavirus vaccines (mRNA), and tuberculosis diagnostic reagents and drugs.
__ Hualan Bio, the company's blood products cover a wide range of products such as human albumin, globulin and coagulation factors.
__Hualan Vaccine, the company is committed to providing key raw materials and drug intermediates for large-scale biopharmaceutical companies at home and abroad.
All of these companies are leading stocks in the pharmaceutical sector, and investors can choose the right stocks to invest in according to their risk tolerance and investment objectives.
This is the end of the introduction of lagging pharmaceutical stocks can buy.